ProfileGDS5678 / 1427764_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 64% 64% 65% 63% 63% 63% 63% 61% 65% 64% 64% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8287363
GSM967853U87-EV human glioblastoma xenograft - Control 23.8183764
GSM967854U87-EV human glioblastoma xenograft - Control 33.8219464
GSM967855U87-EV human glioblastoma xenograft - Control 43.9116665
GSM967856U87-EV human glioblastoma xenograft - Control 53.7593763
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8111663
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8377163
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7933463
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6549261
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9091265
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8045264
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7858164
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.818864
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8093364